Good Sam Club Open Roads Forum: Around the Campfire: 2019–2022 CORONAVIRUS PANDEMIC POSTINGS
Open Roads Forum Already a member? Login here.   If not, Register Today!  |  Help

Newest  |  Active  |  Popular  |  RVing FAQ Forum Rules  |  Forum Posting Help and Support  |  Contact  

Search:   Advanced Search

Search only in Around the Campfire

Open Roads Forum  >  Around the Campfire  >  General Topics

 > 2019–2022 CORONAVIRUS PANDEMIC POSTINGS

Reply to Topic  |  Subscribe  |  Print Page  |  Post New Topic  | 
Page of 175  
Prev  |  Next
RambleOnNW

Pacific Northwest

Senior Member

Joined: 08/06/2010

View Profile



Good Sam RV Club Member


Posted: 04/12/21 04:40pm Link  |  Quote  |  Print  |  Notify Moderator

Saw this website posted on the news. A developer has put up a free website as a public service that collects all the available pharmacy C19 appointments by state and updates every minute. Nice user interface.

https://www.vaccinespotter.org/

BCSnob

Middletown, MD

Senior Member

Joined: 02/23/2002

View Profile



Posted: 04/14/21 11:20am Link  |  Quote  |  Print  |  Notify Moderator

Moderna’s mRNA vaccine was designed to produce the protein sequence that matches the sequence of the spike protein in the original variant. A preprint was posted on a study by Moderna (with Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health) where they have developed an mRNA vaccine that was designed to match the protein sequence of the spike protein in the South African variant.

They tested this new vaccine as a booster in mice already vaccinated with their first vaccine and they tested this new vaccine as a mixture with their original vaccine in mice that had never been vaccinated. Both vaccine tests (booster or new bi-valent vaccine) lead to strong antibody production in mice.

The booster vaccine increased the antibodies against the original variant and added antibodies against the South African variant. The bivalent vaccine elicited antibodies against the original and the South African variants.

Antibodies against the original variant provide variable cross reactivity to the other variants with the least cross reactivity to the South African variant. Antibodies against South African variant are expected to provide variable cross reactivity to the other variants. Having antibodies against both variants is expected to provide more protection to all current variants and potential new variants than having antibodies against just the original variant.

This study is an early step towards clinical trials of a booster vaccine and a new vaccine that provides better protection against the evolving virus.

bioRxiv preprint doi: https://doi.org/10.1101/2021.04.13.439482

* This post was last edited 04/14/21 12:33pm by BCSnob *   View edit history

BCSnob

Middletown, MD

Senior Member

Joined: 02/23/2002

View Profile



Posted: 04/16/21 01:59pm Link  |  Quote  |  Print  |  Notify Moderator

Here is a review of a recent preprint on the rates of blood clots in the general population, those infected by COVID-19, infected with influenza, or vaccinated for COVID-19. The rates of blood clots were higher in those who were infected with Covid-19 (39/million) than those receiving either mRNA vaccine (4.1/million). In the USA there were 8 reported cases of blood clots after receiving the J&J vaccine out of the 7.4 million vaccinations with J&J (1.1/million).

Quote:

expert reaction to preprint looking at incidence of rare cerebral venous thrombosis (CVT) following COVID-19 infection compared to incidence after vaccination or influenza
science media centre > roundups for journalists >


The study was able to conclude, however, that the risk of CVT is increased, compared to the general population, in both people who have Covid-19 disease, and in people receiving the vaccines in the study. It found the following rates of disease:

Background rate of CVT: 0.41 per million people over any two-week period.

Rate of CVT following diagnosis of Covid-19: 39.0 per million people (95% CI, 25.2–60.2).

Rate of CVT following diagnosis of influenza: 0.0 per million people (95% CI 0.0–22.2).

Rate of CVT after receiving BNT162b2 or mRNA-1273 vaccine: 4.1 per million people (95% CI, 1.1–14.9)

Rate of PVT following Covid-19 disease: 436.4 per million people (95% CI, 382.9-497.4).

Rate of PVT following influenza: 98.4 per million people (95% CI, 61.4-157.6) after influenza.

Rate of PVT following mRNA vaccination: 44.9 per million people (95% CI, 29.7-68.0).


Btw the use of oral contraceptives increases the risk of CVT to about the risk of getting one of the Covid-19 vaccines.

Hormonal Contraceptives and Cerebral Ven........k: A Systematic Review and Meta-Analysis

* This post was last edited 04/16/21 03:20pm by BCSnob *   View edit history

rommroma557

USA

New Member

Joined: 03/16/2021

View Profile


Offline
Posted: 04/30/21 08:43am Link  |  Quote  |  Print  |  Notify Moderator

----------
Please post personal experiences with vaccines here:

Personal Covid Experiences

This site is for latest technical information and updates. Thanks.
(Mod)

* This post was edited 04/30/21 09:09am by an administrator/moderator *

MEXICOWANDERER

las peñas, michoacan, mexico

Senior Member

Joined: 06/01/2007

View Profile


Offline
Posted: 05/09/21 01:44pm Link  |  Quote  |  Print  |  Notify Moderator

A question:

In the confusion of data and sensational news generated headlines...

Is the bottom line the mutant COVID-19 virus strains do not materially affect the percentage of fully immunized people that need to be hospitalized with threatening COVID-19 symptoms?

Or to put it inversely, the new mutant strains only affect the number of breakout patients? Testing positive with mild or no symptoms.

Thank you for sharing.

BCSnob

Middletown, MD

Senior Member

Joined: 02/23/2002

View Profile



Posted: 05/10/21 06:03am Link  |  Quote  |  Print  |  Notify Moderator

This is a good perspective article published in the Journal of the American Medical Association which touches on your concerns.

COVID-19 Vaccines vs Variants—Determining How Much Immunity Is Enough
JAMA. 2021;325(13):1241-1243

MEXICOWANDERER

las peñas, michoacan, mexico

Senior Member

Joined: 06/01/2007

View Profile


Offline
Posted: 05/10/21 04:30pm Link  |  Quote  |  Print  |  Notify Moderator

Thank you.

BCSnob

Middletown, MD

Senior Member

Joined: 02/23/2002

View Profile



Posted: 05/12/21 10:05am Link  |  Quote  |  Print  |  Notify Moderator

Here is a preprint of a study I expected would occur.

The current vaccines introduce a protein (immunogen) that mimics the RBD of the "wild type" (original variant) of SARS-Cov-2 into the body where the immune response develops antibodies against the RBD of the virus. The RBD is a protein with a specific sequence of amino acids (RNA version of DNA). The new variants have different sequences in the RBD and this impacts the ability of antibodies against the wild type RBD to protect against infection (neutralization) by the new variants.

In the study, the authors evaluated sequence changes in the RBD to determine the ability of antibodies against these hypothetical variants to protect against the current SARS-Cov-2 variants. All of this work was performed with computer models.

The authors then selected the 5 best hypothetical RBDs to test in mice as possible vaccines. The neutralization ability of the antibodies produced by these vaccines were tested against the wild type and the new variants of SARS-Cov-2.

Quote:

These results demonstrate that a handful of amino acid changes to the RBD can dramatically improve the protective antibody response. A 30-fold increase in neutralizing antibody titers is equivalent to lengthening the lifetime of neutralizing antibodies by approximately five half-lives of decay, suggesting that immunogens would confer a much longer duration of antibody-mediated protection than WT RBD. Additionally, this 30-fold enhancement is greater than the 1.5-12 fold reduction in neutralizing potential against new SARS-CoV-2 variants, such as B.1.351, suggesting that these immunogens could increase the breadth of protection, in addition to the duration.


Quote:

Regardless of the (vaccine) platform, these amino acid changes would be expected to increase RBD stability, enhance the protective immune response, and lengthen the lifetime and breadth of protection conferred by a SARS-CoV-2 vaccine.


Design of the SARS-CoV-2 RBD vaccine ant........ improves neutralizing antibody response
bioRxiv preprint doi: https://doi.org/10.1101/2021.05.09.443238

Deb and Ed M

SW MI & Space Coast, FL USA

Senior Member

Joined: 06/07/2004

View Profile



Posted: 05/13/21 07:25am Link  |  Quote  |  Print  |  Notify Moderator

Mark, am I reading between the lines correctly, that assuming we get a booster shot tweaked for the variants, that we may not need a *yearly* booster?? Or is that too hard to predict, given how often this virus is mutating?

BCSnob

Middletown, MD

Senior Member

Joined: 02/23/2002

View Profile



Posted: 05/13/21 10:21am Link  |  Quote  |  Print  |  Notify Moderator

There are two aspects that need to be addressed in order to not need periodic boosters.
1) The vaccine induces antibodies against all variants as the virus mutates.
2) The vaccine induces long term immunity (years to lifetime).

I think the work in the recent article suggests it will be possible to manufacture vaccines that induce antibodies to protect against all possible variants that will bind to the ace2 receptor (not all viral mutations occur in the RBD and not all mutations in the RBD lead to strong binding to the RBD); this vaccine may have multiple immunogens.

The second aspect will require long term studies to measure duration of immunity.

Reply to Topic  |  Subscribe  |  Print Page  |  Post New Topic  | 
Page of 175  
Prev  |  Next

Open Roads Forum  >  Around the Campfire  >  General Topics

 > 2019–2022 CORONAVIRUS PANDEMIC POSTINGS
Search:   Advanced Search

Search only in Around the Campfire


New posts No new posts
Closed, new posts Closed, no new posts
Moved, new posts Moved, no new posts

Adjust text size:




© 2022 CWI, Inc. © 2022 Good Sam Enterprises, LLC. All Rights Reserved.